Navigation Links
ArteFill 5-Year Data to Be Presented at American Society for,Aesthetic Plastic Surgery Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Apr 17, 2007 - Artes Medical, Inc. (Nasdaq:ARTE), a medical technology company focused on developing, manufacturing and commercializing a new category of aesthetic injectable products for men and women, today announced that the final 5-year safety and efficacy data for ArteFill(R), the Company's FDA-approved non-resorbable injectable dermal filler will be presented at the national meeting of the American Society for Aesthetic Plastic Surgery (ASAPS) on April 20, 2007 in New York City by Steven R. Cohen, MD, FACS, Clinical Professor, Division of Plastic Surgery, University of California, San Diego, School of Medicine and lead ArteFill clinical investigator. The session will also include a live patient workshop to demonstrate the proper techniques in the treatment of nasolabial folds (smile lines).

The 5-year clinical data represents the culmination of a significant follow-up study of 145 patients who were treated with ArteFill in the Company's U.S. clinical trial. The Company has submitted the data to the FDA in order to enhance the product labeling of ArteFill.

About ArteFill(R)

ArteFill is the first and only FDA-approved non-resorbable injectable dermal filler for the correction of wrinkles known as smile lines or nasolabial folds. The unique microspheres in ArteFill are not absorbed by the body and therefore provide the first-of-its-kind permanent support for long-lasting wrinkle correction in one to two treatments.

ArteFill was approved by the FDA in October 2006 based on data from the Company's 12-month controlled, randomized, double-masked, multi-center U.S. clinical trial, which compared outcomes for patients treated with ArteFill with those of patients treated with the leading bovine collagen-based filler. At the 6-month evaluation, which was the primary efficacy evaluation period for the clinical trial, the wrinkle correction in patients treated with Arte
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:11/22/2014)... , 21 de noviembre de 2014  BioClinica®, ... clínicos externalizados y tecnologías eClinical, ha indicado un ... ,seguimiento inteligente, para el seguimiento basado en el ... amplía el concepto del seguimiento basado en el ... las visitas de seguimiento o cambio de los ...
(Date:11/22/2014)... Statistics released from a number of organizations show that ... holidays, beginning with Thanksgiving eve, which is now termed ... data, highlighted in an Infographic released by ... annual Sober Days for the Holidays public awareness ... increased rates of DUI injuries and deaths during the ...
(Date:11/22/2014)... 2014  Particle Sciences, Inc (PSI), the leading ... manufactured a new innovative vaginal ring for Ladee ... arm of Exeltis Pharmaceuticals.  According to Bruce ... Particle Sciences, "This vaginal ring was developed for ... and modeling expertise.  We are thrilled it is ...
Breaking Medicine Technology:El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3Alarming Stats Show Holiday Drinking an Issue for Many 2Particle Sciences' Clinical Trial Supplies Group Manufactures Innovative Vaginal Ring 2
... Time - SOUTH SAN FRANCISCO, Calif., March 16 ... biopharmaceutical company focused on oncology, today reported financial results ... 2008, and provided a corporate update. "During the fourth ... goal of developing picoplatin as an oncology platform compound ...
... announced that it has initiated a Phase II clinical ... ulcers. HP802-247 is a topical spray containing living keratinocytes ... effectiveness of two cell concentrations and two dosing frequencies ... placebo plus standard care, in healing venous leg ulcers ...
Cached Medicine Technology:Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 2Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 3Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 4Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 5Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 6Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 7Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 8Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 9Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers 2Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers 3
(Date:11/22/2014)... 22, 2014 Forbes Living TV ... pleased to announce that Ashley Lombardo and friend Candy ... , Ms. Lombardo entered friend Candy Sherman to ... wrote of how her friend is courageously battling lung ... single mom. Despite medical bills piling up and the ...
(Date:11/22/2014)... November 22, 2014 Developers and plugin specialist ... plugin entitled FCPX 3D Model bringing the impossible to ... allows users to add obj files to FCPX enabling 3d ... “Blurring the line between professional and armature, FCPX 3D Model ... Film Studios allows Final Cut Pro X users to upload ...
(Date:11/22/2014)... News) -- A clinical trial of hydroxyurea therapy for ... year early because the results show it is a ... reduce the risk of stroke. The announcement about ... in the United States and Canada, was made this ... Institute (NHLBI). Researchers compared monthly blood transfusions with ...
(Date:11/22/2014)... widely used heart drug digoxin is associated with increased ... the heart rhythm disorder atrial fibrillation but no evidence ... fibrillation is a common form of irregular heartbeat that ... stroke among older Americans. Digoxin has been used for ... the authors of the new study said, and many ...
(Date:11/21/2014)... 21, 2014 Body Well Therapy, a leading ... accepts Spafinder massage gift cards and gift ... massage in all service areas including throughout Florida and the ... go to the spa at all to redeem your Spafinder ... Body Well. "We may not be able to transport all ...
Breaking Medicine News(10 mins):Health News:Forbes Living TV Announces Winner of Thanksgiving #PayItForward Contest 2Health News:Pixel Film Studios released FCPX 3D Model plugin Exclusively for Final Cut Pro X 2Health News:Sickle Cell Anemia Treatment So Successful in Kids That Trial Is Halted 2Health News:Treating Irregular Heartbeat With Digoxin May Come With Risks 2Health News:Treating Irregular Heartbeat With Digoxin May Come With Risks 3Health News:Body Well Mobile Massage Announces Acceptance of Spafinder Gift Cards for In Home Massage, Hotel Massage for Travelers 2
... The following is a,statement of William V. ... Bush today let down America,s children and protected ... that would,increase the federal cigarette tax by 61 ... Health Insurance Program (SCHIP). The President has missed,an ...
... LARGO, Fla. and RIDGEFIELD, Conn., Oct. 3 ,Unilens Vision ... Eschenbach Optik announced today that Eschenbach Optik has been ... Lens.,Eschenbach Optik of America, Inc. will serve as the ... GmbH + Co will be the,exclusive distributor in the ...
... Comments on Company,s Restructuring, Recovery and Revitalization, ... of,PainCare Holdings, Inc. (Amex: PRZ ), one ... surgical solutions and services, today issued,the following corporate ... impact and support the Company,s refined long term,growth ...
... Free Patient Education Campaign Urges Enrollment, LOS ANGELES, ... a,significant number of clinical trials are being conducted to ... chronic and potentially fatal,autoimmune disease that affects more than ... A key question that clinical trials answer is, ...
... ... Workplace, Company Develops Community Educational Partnership with St. Joseph Health ... System in Orange County, IRVINE, Calif., ... in the United States, has opened 14 health care,centers at CVS/pharmacy stores in Los ...
... issued,today by the American Heart Association/American Stroke Association: ... offers,solutions The American Heart Association/American Stroke Association ... identify disparities,in healthcare and help patients get the ... published in the Oct. 3 issue of the ...
Cached Medicine News:Health News:President's Veto of Bill to Increase Cigarette Tax, Fund SCHIP Benefits Big Tobacco at Expense of America's Kids 2Health News:Unilens Names Eschenbach Optik Exclusive Worldwide Distributor of the UniVision(R) Low Vision Lens 2Health News:Unilens Names Eschenbach Optik Exclusive Worldwide Distributor of the UniVision(R) Low Vision Lens 3Health News:PainCare Reports on Key Corporate Developments 2Health News:PainCare Reports on Key Corporate Developments 3Health News:PainCare Reports on Key Corporate Developments 4Health News:PainCare Reports on Key Corporate Developments 5Health News:Clinical Trials for Lupus Underway After Decades of Drought 2Health News:An Innovation in Health Care Opens at CVS/pharmacy Stores in Los Angeles Metro Area 2Health News:An Innovation in Health Care Opens at CVS/pharmacy Stores in Los Angeles Metro Area 3Health News:An Innovation in Health Care Opens at CVS/pharmacy Stores in Los Angeles Metro Area 4Health News:An Innovation in Health Care Opens at CVS/pharmacy Stores in Los Angeles Metro Area 5Health News:An Innovation in Health Care Opens at CVS/pharmacy Stores in Los Angeles Metro Area 6Health News:News From the American Heart Association/American Stroke Association 2Health News:News From the American Heart Association/American Stroke Association 3Health News:News From the American Heart Association/American Stroke Association 4Health News:News From the American Heart Association/American Stroke Association 5Health News:News From the American Heart Association/American Stroke Association 6
... The dual-electrode SPL defibrillator ... electrode design, offering the flexibility ... lead. Designed for the physician ... two shocking coils, the SPL ...
The Livewire cannulator offers improved access to the coronary sinus by combining the ergonomic Livewire steering mechanism with numerous specialized features....
... Stockert 70 RF Generator introduces ... lab every day, in every ... 70 and the CARTO EP ... Ablation Catheter provide clinicians with ...
... The Integrity family of pacemakers ... advanced and truly automatic devices ... Offering an unparalleled combination of ... the system builds on the ...
Medicine Products: